Earth Science Tech Inc. (OTCQB: ETST), a healthcare, pharmacy, and telemedicine holding company, has uplisted to the OTCQB Venture Market as of Sept. 17, 2026, marking a significant step in its fiscal 2027 growth strategy. The uplisting follows a strong first quarter in which revenue increased 3% to $9.0 million and net income rose 57% to $715,697, according to the company. These results underscore the company's improving operational efficiency and financial health.
In addition to the uplisting, Earth Science Tech has completed the acquisitions of Meduvo LLC, a compounding pharmacy, and Zoolzy LLC, a pharmaceutical distributor. These acquisitions are expected to expand the company's opportunities in human therapeutics and animal health, further broadening its business portfolio. The integration of Meduvo and Zoolzy aligns with Earth Science Tech's strategy to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment.
At its annual shareholder meeting on Aug. 31, investors approved several measures supporting potential future uplisting to the Nasdaq or NYSE, the planned retirement of the dual-class voting structure, and a new non-dilutive executive compensation framework. These governance changes reflect the company's commitment to enhancing corporate governance and aligning management interests with shareholder value. The retirement of the dual-class structure is particularly notable as it could make the company more attractive to institutional investors and improve its chances for a future uplisting to a major exchange.
The uplisting to the OTCQB Venture Market is a key milestone for Earth Science Tech, as it may increase visibility among investors and improve liquidity. The OTCQB is a premier market for early-stage and developing U.S. and international companies, and meeting its standards requires a company to be current in its reporting and undergo an annual verification and management certification process. For Earth Science Tech, this move could lead to a broader investor base and enhanced credibility in the marketplace.
Earth Science Tech operates as a diversified holding company focused on the health and wellness sector. Its principal operating strategy is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The company's healthcare operations are supported by investments in real estate and asset management activities and a consumer products business. The core of the company's value proposition is the seamless integration of patient care, from consultation to fulfillment, achieved through the synergy of specialized subsidiaries.
For investors, the combination of strong financial performance, strategic acquisitions, and governance improvements presents a compelling growth narrative. The company's focus on operational efficiency and broadening its business portfolio could drive further revenue and earnings growth. Additionally, the potential for a future uplisting to the Nasdaq or NYSE could provide additional upside. However, investors should consider the risks associated with integration of acquisitions and the competitive healthcare landscape. The full article can be viewed at https://ibn.fm/hrUOF. For more information, visit www.EarthScienceTech.com. The latest news and updates relating to ETST are available in the company's newsroom at https://ibn.fm/ETST.
About BioMedWire: BioMedWire ("BMW") is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
